Oncotelic Therapeutics (OTCQB: OTLC) has announced an update on the advancement of its proprietary AI platform and robotic integration toward commercialization, following the integration of approximately 28 million scientific abstracts.
According to Oncotelic, the PDAOAI robotics platform, jointly developed with TechForce Robotics, is designed to improve operational efficiency, reduce reliance on manual processes, and support compliance across pharmaceutical development and manufacturing.
In a statement, Dr. Vuong Trieu, chairman and CEO of Oncotelic, commented, “We are moving from data to real-world application. By embedding the totality of scientific knowledge into robotics, we can look to transform how drugs are developed and produced, not just for us, but for the broader industry.”
